Elaine Jones, executive director of Pfizer Venture Investments, will be an observer to Neuronetics' board and said: "Pfizer has had a longstanding interest in treating depression."

At the initial closing of the financing, Radius received gross proceeds of $22m in equity and $6.25m in debt, and $1.4m of preferred stock was issued to Ipsen in lieu of a cash milestone payment.

As part of a licensing agreement, BioCritica will acquire the US development and commercialization rights to Lilly's Xigris treatment for severe sepsis and the rights to potentially acquire several critical care compounds currently in pre-clinical development at Lilly.

In September, Pfizer through its corporate venturing unit invested $5m in TetraLogic.

Takahiro Mukahira of MP Healthcare Venture Management will be a board observer at GenKyoTex.

BoSci invested $30m in 2004 with an option to acquire the company and the company had in total raised about $180m before this latest round, according to news provider In Vivo

Healthbox will run a competition to find 10 entrepreneurial teams from around the US to participate in a three-month programme and receive $50,000 in seed capital.

The $750m purchase price for Advanced BioHealing gives a 13 times return for Safeguard, which invested $26m.

In February, Orphazyme Aps raised DKr22m ($4m) in a seed stage round from a consortium including local investor, Novo.